Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
暂无分享,去创建一个
J. Gribben | D. Neuberg | C. Croce | M. Capasso | F. McClanahan | Shaun Miller | William P. Day | E. Kotsiou | J. Riches
[1] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[2] C. Horn,et al. Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T‐cells in chronic lymphocytic leukemia , 2014, International journal of cancer.
[3] John T. Chang,et al. Molecular regulation of effector and memory T cell differentiation , 2014, Nature Immunology.
[4] G. Lenz,et al. Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation. , 2014, Cancer discovery.
[5] J. Nikolich-Žugich,et al. Aging of the T Cell Compartment in Mice and Humans: From No Naive Expectations to Foggy Memories , 2014, The Journal of Immunology.
[6] U. Klein,et al. Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy. , 2014, Blood.
[7] D. Weisenburger,et al. Chronic Lymphocytic Leukemia Cells in a Lymph Node Microenvironment Depict Molecular Signature Associated with an Aggressive Disease , 2014, Molecular medicine.
[8] J. Taube,et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.
[9] C. Croce,et al. Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia , 2014, Leukemia.
[10] J. Gribben,et al. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. , 2014, Seminars in cancer biology.
[11] E. Remmerswaal,et al. CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia. , 2014, Blood.
[12] H. Pircher,et al. Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype , 2013, Cancer Immunology, Immunotherapy.
[13] Keith M. Thompson,et al. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. , 2013, Cell reports.
[14] A. Legat,et al. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion , 2013, Nature Immunology.
[15] Michael Loran Dustin,et al. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis , 2013, The Journal of experimental medicine.
[16] J. Gribben,et al. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. , 2013, Blood.
[17] J. Gribben,et al. Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications. , 2013, Hematology/oncology clinics of North America.
[18] J. Gribben,et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. , 2013, Blood.
[19] D. Rossi,et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia , 2012, Haematologica.
[20] W. Wilson,et al. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. , 2012, Blood.
[21] J. Gribben,et al. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. , 2012, Blood.
[22] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[23] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[24] Takashi Saito,et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 , 2012, The Journal of experimental medicine.
[25] Peter Vogel,et al. Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .
[26] C. Fegan,et al. Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression , 2011, Clinical Cancer Research.
[27] E. Wherry. T cell exhaustion , 2011, Nature Immunology.
[28] R. Greil,et al. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL , 2011, Leukemia.
[29] Annette Lee,et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. , 2011, Blood.
[30] Michael J. Zilliox,et al. Phenotype, Function, and Gene Expression Profiles of Programmed Death-1hi CD8 T Cells in Healthy Human Adults , 2011, The Journal of Immunology.
[31] Steven J. M. Jones,et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers , 2011, Nature.
[32] Richard Sherry,et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.
[33] Antonio Polley,et al. Tissue-Specific Differences in PD-1 and PD-L1 Expression during Chronic Viral Infection: Implications for CD8 T-Cell Exhaustion , 2009, Journal of Virology.
[34] John Quackenbush,et al. Eμ-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction , 2009, Proceedings of the National Academy of Sciences.
[35] G. Freeman,et al. Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade , 2008, Proceedings of the National Academy of Sciences.
[36] J. Byrd,et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.
[37] Marcos González,et al. Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients. , 2008, Blood.
[38] J. Salisbury,et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. , 2008, Blood.
[39] M. Azuma,et al. Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer , 2007, Clinical Cancer Research.
[40] Yoshimasa Tanaka,et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.
[41] Annelieke Jaspers,et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. , 2007, Blood.
[42] R. Koup,et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection , 2006, The Journal of experimental medicine.
[43] Philip J. R. Goulder,et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.
[44] J. Gribben,et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. , 2005, The Journal of clinical investigation.
[45] M. Azuma,et al. Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.
[46] R. Koup,et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. , 2003, Journal of immunological methods.
[47] C. Croce,et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[48] M. Chilosi,et al. Chronic B cell malignancies and bone marrow microenvironment. , 2002, Seminars in cancer biology.
[49] Michael F Denny,et al. Superantigen-Induced T Cell:B Cell Conjugation Is Mediated by LFA-1 and Requires Signaling Through Lck, But Not ZAP-701 , 2001, The Journal of Immunology.
[50] G. Freeman,et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.
[51] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[52] T. Honjo,et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.
[53] B. Clarkson,et al. Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies. , 1982, Journal of immunology.
[54] F. Herrmann,et al. Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type. , 1982, Clinical and experimental immunology.
[55] D. Catovsky,et al. Clinical significance of T-cells in chronic lymphocytic leukaemia. , 1974, Lancet.
[56] Antonio Polley,et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.
[57] A. Philippon,et al. REFERENCES CONTENT ALERTS Updated information and services can be found at: , 1999 .